Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study

NCT07324473 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinomas
Resistance to Immunotherapy
Immunomodulation
Drug Repurposing

Interventions

DRUG: The triple-therapy strategy of Ivarmacitinib, Apatinib, and Camrelizumab

Sponsor

First Affiliated Hospital of Chongqing Medical University